PureTech Health (GB:PRTC) has released an update.
PureTech Health’s entity Seaport Therapeutics revealed promising data from clinical trials of SPT-300, a potential oral treatment for mood and anxiety disorders, at the Society of Biological Psychiatry Annual Meeting. Demonstrating nine times the bioavailability of natural allopregnanolone and substantial stress-cortisol reduction, SPT-300 is expected to advance into later-stage clinical studies. The results endorse the efficacy of Seaport’s Glyph platform in enhancing drug absorption and targeting neuropsychiatric conditions.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
